Hopkins, Brian T.’s team published research in Journal of Medicinal Chemistry in 2022 | CAS: 3934-20-1

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Application In Synthesis of 2,4-Dichloropyrimidine

In 2022,Hopkins, Brian T.; Bame, Eris; Bajrami, Bekim; Black, Cheryl; Bohnert, Tonika; Boiselle, Carrie; Burdette, Doug; Burns, Jeremy C.; Delva, Luisette; Donaldson, Douglas; Grater, Richard; Gu, Chungang; Hoemberger, Marc; Johnson, Josh; Kapadnis, Sudarshan; King, Kris; Lulla, Mukesh; Ma, Bin; Marx, Isaac; Magee, Tom; Meissner, Robert; Metrick, Claire M.; Mingueneau, Michael; Murugan, Paramasivam; Otipoby, Kevin L.; Polack, Evelyne; Poreci, Urjana; Prince, Robin; Roach, Allie M.; Rowbottom, Chris; Santoro, Joseph C.; Schroeder, Patricia; Tang, Hao; Tien, Eric; Zhang, Fengmei; Lyssikatos, Joseph published an article in Journal of Medicinal Chemistry. The title of the article was 《Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis》.Application In Synthesis of 2,4-Dichloropyrimidine The author mentioned the following in the article:

Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early stage of MS, inflammation is the primary driver of the disease progression. There remains an unmet need to develop high efficacy therapies with superior safety profiles to prevent the inflammation processes leading to disability. Herein, we describe the discovery of BIIB091 (I), a structurally distinct orthosteric ATP competitive, reversible inhibitor that binds the BTK protein in a DFG-in confirmation designed to sequester Tyr-551, an important phosphorylation site on BTK, into an inactive conformation with excellent affinity. Preclin. studies demonstrated BIB091 to be a high potency mol. with good drug-like properties and a safety/tolerability profile suitable for clin. development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. In the experiment, the researchers used 2,4-Dichloropyrimidine(cas: 3934-20-1Application In Synthesis of 2,4-Dichloropyrimidine)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Application In Synthesis of 2,4-Dichloropyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia